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Characterization of CD81CD571 T cells in patients with
acute myocardial infarction
Hee Tae Yu1,4, Jong-Chan Youn1,2,4, Jino Lee1, Seunghyun Park1, Ho-Seok Chi1, Jungsul Lee3,
Chulhee Choi3, Sungha Park2, Donghoon Choi2, Jong-Won Ha2,4 and Eui-Cheol Shin1,4
Although T cells are known to be involved in the pathogenesis of coronary artery disease, it is unclear which subpopulation
of T cells contributes to pathogenesis in acute myocardial infarction (MI). We studied the immunological characteristics
and clinical impact of CD81CD571 T cells in acute MI patients. The frequency of CD571 cells among CD81 T cells was
examined in peripheral blood sampled the morning after acute MI events. Interestingly, the frequency of CD571 cells in
the CD81 T-cell population correlated with cardiovascular mortality 6 months after acute MI. The immunological
characteristics of CD81CD571 T cells were elucidated by surface immunophenotyping, intracellular cytokine staining
and flow cytometry. Immunophenotyping revealed that the CD81CD571 T cells were activated, senescent T cells with
pro-inflammatory and tissue homing properties. Because a high frequency of CD81CD571 T cells is associated with
short-term cardiovascular mortality in acute MI patients, this specific subset of CD81 T cells might contribute to acute
coronary events via their pro-inflammatory and high cytotoxic capacities. Identification of a pathogenic CD81 T-cell
subset expressing CD57 may offer opportunities for the evaluation and management of acute MI.
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INTRODUCTION
It is well known that inflammation plays a key role in the
pathogenesis of coronary artery disease.1–3 The pathogenic role
of T cells in atherosclerosis is well described in animal mod-
els.4–7 Recently, the association of pathogenic T cells with acute
coronary syndrome in humans was addressed.8–10 However, it
remains unclear which specific subpopulation of T cells plays a
major role in acute coronary syndrome. CD41CD28null T cells
have been reported to contribute to acute coronary syn-
drome,11,12 and expansion of CD41CD28null T cells is strongly
associated with the recurrence of acute coronary events.11
Furthermore, in diabetic patients, an increased frequency of
CD41CD28null T cells correlated with poor outcome after an
acute coronary event.12 However, a role for CD81 T cells in
human coronary artery disease has been identified less than for
CD41 T cells.13
The accumulation of CD28null T cells is one of the most prom-
inent changes during the immune aging process.14 Similarly, the
expression of CD57, a terminally sulfated glycan carbohydrate
epitope, on T cells is currently considered to be a surrogate mar-
ker of replicative senescence of T cells.15 CD571 T cells fail to
proliferate after antigen-specific stimulation in vitro and are highly
vulnerable to activation-induced apoptosis.16,17 Furthermore, it
was demonstrated that replicative senescence of T cells is better
defined by the expression of CD57 than by a lack of CD28
expression, as determined by measurement of the T-cell receptor
excision circle content and of the proliferative ability of T cells.17
Notably, while CD571 T cells have been shown to be associated
with various inflammatory diseases,18–22 the pathogenic roles of
CD571 T cells have yet to be elucidated in coronary artery disease.
In the present study, we assessed the immunological char-
acteristics of CD571 T cells, particularly CD81CD571 T cells,
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in patients following acute myocardial infarction (MI) and
analyzed their impact on clinical outcome.
MATERIALS AND METHODS
Study population
The present study included 58 prospectively and consecutively
enrolled patients diagnosed with acute MI at the Severance
Hospital from April 2010 to August 2010. Acute MI was
defined as follows: (i) typical ischemic chest pain lasting for
more than 30min; ii) significant elevation of the ST segment or
depression of two contiguous leads monitored by a standard
12-lead electrocardiogram; and iii) either elevation of the cre-
atine kinase-MB isoform to greater than twice the normal
upper limit or a rise in troponin T exceeding 0.1 ng/ml.
Patients underwent a physical examination, electrocardiogram
and laboratory examination at the time of initial enrollment.
Whole blood was placed into an ACD anti-coagulated tube the
morning after the patient was admitted to the hospital. Patients
with a history of chronic inflammatory disease or who were
taking anti-inflammatory medications were excluded from this
study. The baseline characteristics of the study population are
summarized in Table 1. Informed consent was provided by all
subjects, and the study was approved by the Institutional
Review Board (Yonsei University College of Medicine).
Immunophenotyping analysis of peripheral blood
mononuclear cells (PBMCs)
PBMCs were isolated from whole blood using Ficoll-Hypaque
(GE Healthcare, Uppsala, Sweden) and immediately analyzed
for CD57 and CD28 expression. Any remaining PBMCs were
cryopreserved and were later thawed and analyzed by flow
cytometry. The cells were stained with fluorochrome-
conjugated monoclonal antibodies against surface antigens
for 20 min at 4 uC. The antibodies used included anti-
CD3-Horizon V500, anti-CD4-PE-Cy7, anti-CD8-APC-H7,
Table 1 Clinical characteristics and laboratory findings of analyzed subjects
Survival (n548) Cardiovascular mortality (n57) P value
Demographic data
Age (years) 65.6613.1 74.468.4 0.089
Sex (M/F) 33 : 15 6 : 1 0.660
STEMI/NSTEMI 26 : 22 2 : 5 0.252
Extent of CAD (1-VD/2-VD/3-VD) (%) 22.7/40.9/36.4 0/28.6/71.4 0.163
Infarct-related arteries (LM/LAD/LCx/RCA) (%) 0/48.8/14.6/36.6 20.0/40.0/0/40.0 0.029*
Mode of treatment (PCI/CABG/medical) (%) 87.5/0/12.5 57.1/14.3/28.6 0.013*
Door-to-balloon time (minutes; in STEMI) 155.06470.2 70.0622.6 0.804
TIMI flow before PCI (0/1/2/3) 19/2/4/21 2/0/1/4 0.820
TIMI flow after PCI (0/1/2/3) 1/0/0/45 1/0/1/5 0.009*
Laboratory findings
Hemoglobin (g/dl) 13.562.4 11.361.6 0.021*
BUN (mg/dl) 18.567.3 32.2610.1 ,0.001*
Cr (mg/dl) 1.160.5 3.862.2 0.019*
Total cholesterol (mg/dl) 155.8641.5 124.7643.4 0.071
Triglyceride (mg/dl) 109.7662.4 88.9641.7 0.398
HDL cholesterol (mg/dl) 39.7611.2 32.069.6 0.093
LDL cholesterol (mg/dl) 93.8639.5 71.0629.2 0.149
hsCRP (mg/l) 33.2655.6 105.5687.7 0.073
Initial CK-MB (ng/ml) 27.9668.1 41.9657.7 0.607
Peak CK-MB (ng/ml) 141.06162.5 69.4663.9 0.257
Initial Troponin-T (ng/ml) 0.962.7 2.063.6 0.345
Peak Troponin-T (ng/ml) 1.463.2 4.064.4 0.173
NT-proBNP (pg/ml) 1613.863506.2 18591.7615332.7 0.026*
Echocardiographic data
LVEF (%) 53.7613.6 41.4610.8 0.027*
LVEDD (mm) 50.065.2 53.367.3 0.147
LVESD (mm) 35.065.9 41.768.3 0.011*
LA Vol. index (ml/m2) 28.2610.9 37.4621.0 0.291
Abbreviations: BUN, blood urea nitrogen; CABG, coronary artery bypass surgery; CAD, coronary artery disease; CK-MB, creatine kinase MB; Cr,
creatinine; HDL, high-density lipoprotein; hsCRP, high sensitivity C-reactive protein; LAD, left anterior descending artery; LA Vol. index, left atrial
volume index; LCx, left circumflex artery; LDL, low-density lipoprotein; LM, left main artery; LVEDD, left ventricular end diastolic dimension; LVEF, left
ventricular ejection fraction; LVESD, left ventricular end systolic dimension; NSTEMI, non-ST-segment elevation myocardial infarction; NT-proBNP, N-
terminal pro-brain natriuretic peptide; PCI, percutaneous coronary intervention; RCA, right coronary artery; STEMI, ST-segment elevation myocardial
infarction; TIMI, thrombolysis in myocardial infarction; VD, vessel disease.
Values are presented as a %, or mean6s.d.
*P,0.05 is considered significant.
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anti-CD28-APC, anti-CD45RO-PerCP-Cy5.5, anti-CD56-PE,
anti-CD62L-APC, anti-CD94-FITC, anti-CCR5-PE, anti-
CCR7-PE, anti-PD-1-PE, anti-NKG2D-APC, anti-HLA-DR-
FITC (all from BD Biosciences, San Jose, CA, USA), anti-
CD57-eFluor 450, anti-FasL-PE (both from eBioscience, San
Diego, CA, USA), anti-CX3CR1-FITC (MBL International,
Woburn, MA, USA) and anti-CD127-APC (R&D Systems,
Minneapolis, MN, USA). To access intracellular cytotoxic mole-
cules, PBMCs were fixed and permeabilized using a Fixation/
Permeabilization Buffer Kit (eBioscience) and further stained for
intracellular cytotoxic molecules with anti-perforin-PE, anti-
granzyme A-FITC and anti-granzyme B-APC (all from BD
Biosciences). Multicolor flow cytometry was performed using
an LSR II instrument (BD Biosciences), and FlowJo software
(Treestar, San Carlos, CA, USA) was used to analyze the data.
In vitro stimulation of T cells and intracellular cytokine staining
PBMCs were stimulated with anti-CD3 antibody (100 ng/ml)
for 6 hours. After 1 h of incubation, brefeldin A (GolgiPlug; BD
Biosciences) and monensin (GolgiStop; BD Biosciences) were
added to stimulate intracellular cytokine protein accumulation.
Following surface staining with anti-CD3-horizon V500, anti-
CD4-PE-Cy7, anti-CD8-APC-H7, anti-CD45RO-PerCP-Cy5.5
and anti-CD57-eFluor 450, the cells were fixed and permeabi-
lized using the Fixation/Permeabilization Buffer Kit and further
stained for intracellular cytokines with anti-TNF-a-FITC, anti-
IL-17A-PE and anti-IFN-c-APC (all from BD Biosciences).
To analyze the IL-12/IL-18-responsiveness of the T cells,
PBMCs were cultured in the presence of IL-12 (20 ng/ml;
Peprotech, USA) and IL-18 (100 ng/ml; Peprotech) for 48 h
and then stained for the same surface markers and intracellular
cytokines, with the exception of IL-17A. FACS analysis was
performed using a LSR II flow cytometer (BD Biosciences),
and the data were analyzed using FlowJo software (Treestar,
San Carlos, CA, USA).
Statistical analysis
Continuous variables were reported as the means6s.d.
Categorical variables were summarized by the percentage of the
group total. Independent t-tests were used for continuous vari-
ables, and discrete variables were compared using the Chi-squared
method. Intra-group comparisons were summarized using the
paired t-test, and theWilcoxon signed-rank test was used to verify
the results. Multivariate logistic regression analysis was performed
to identify independent predictors of cardiovascular mortality.
The cumulative incidence of mortality was assessed with the
Kaplan–Meier method. The statistical significance of the curves
was calculated using the log-rank test. Statistical analyses were
performed with SPSS 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
The relationship between the frequency of CD571T cells and
short-term cardiovascular mortality in acute MI patients
During a 6-month follow-up period, seven (12%) events of
cardiovascular mortality and three (5%) events of non-cardio-
vascular mortality occurred among the 58 subjects. First, we
analyzed the frequency of CD571 or CD28null T cells among the
CD81 or CD41 T-cell subset present in the peripheral blood of
the 48 patients who survived MI on the morning after admis-
sion to the hospital and compared the results to the seven cases
of cardiovascular death. CD81 and CD41 T cells were iden-
tified in PBMCs by multicolor flow cytometry by gating single
cells (forward scatter-area vs. forward scatter-height), lympho-
cytes (forward vs. side scatter) and staining for CD3, followed
by staining for CD4 and CD8 (Figure 1a). The frequency
of CD571 cells (Figure 1b; 45.6%67.0% vs. 23.3%615.7%,
P50.001) or CD28null cells (Figure 1c; 42.3%66.9% vs.
24.3%617.7%, P50.011) in the CD81 T-cell subset was sig-
nificantly higher in the group that suffered cardiovascularmor-
tality. We also analyzed the CD41 T-cell subset. The frequency
of CD571 cells in the CD41 T-cell subset was significantly
higher in the cardiovascular mortality group (Figure 1d;
5.6%64.5% vs. 3.0%63.0%, P50.047), while the frequency
of CD28null cells in the CD41 T-cell subset was not different
between the two groups (Figure 1e; 3.6%64.5% vs. 3.1%68.5%,
P50.876). In multivariate analysis considering the age, gender
and left ventricular ejection fraction (LVEF) of the patients,
cardiovascular mortality was only associated with the fre-
quency of CD571 cells in the CD81 T-cell subset (Table 2);
thus, CD81CD571 T cells were a focus of further analyses. In
Figure 1f, representative flow cytometry plots are presented for
CD57 and CD28 expression in the CD81 T-cell population.
Although the CD571 cell population overlapped considerably
with the CD28null cell population (Figure 1f), only the fre-
quency of CD81CD571 cells was independently associated
with short-term cardiovascular mortality. Next, we divided
the patients (48 cases of survival and seven cases of cardio-
vascular mortality) into two groups based upon the median
percentage of CD81CD571 T cells in the peripheral blood, and
compared the survival between the two groups. The group with
the higher frequency of CD81CD571 cells (o25%) suffered
a significantly greater rate of cardiovascular mortality than
the group with the lower frequency of CD81CD571 cells
(P50.004) (Figure 1g).
Immunophenotyping analysis of CD81CD571 T cells from
acute MI patients
Because CD81CD571 T cells were associated with poor pro-
gnosis following acute MI, we examined the immunopheno-
type of the CD81CD571 T cells from acute MI patients.
Compared with the CD81CD572 T cells, the CD81CD571 T
cells expressed significantly higher levels of HLA-DR, PD-1 and
FasL, which are all markers associated with the recent activa-
tion of T cells (Figure 2a). CD81CD571 T cells also showed a
senescent and terminally differentiated phenotype, as deter-
mined by lower levels of CD28 and IL-7Ra expression and
higher levels of CD45RO expression (Figure 2b). Markers
associated with natural killer cells, such as CD56, CD94 and
NKG2D, were overexpressed on CD81CD571 T cells com-
pared with CD81CD572 T cells (Figure 2c). With respect to
chemokine receptors, CD81CD571 T cells expressed higher
levels of tissue-homing markers (CX3CR1 and CCR5;
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Figure 2d) and lower levels of central-homing markers (CCR7
and CD62L; Figure 2e) than CD81CD572 T cells, suggesting
that CD81CD571 T cells are poised to migrate toward
inflamed peripheral tissues. In summary, surface phenotyping
analysis revealed that CD81CD571 T cells are activated, sen-
escent T cells with cytotoxic and tissue-homing properties.
Functional reactivity of CD81CD571 T cells from acute MI
patients
We analyzed the functional characteristics of CD81CD571 T
cells from acute MI patients. First, we performed intracellular
cytokine staining for IFN-c, TNF-a and IL-17A following anti-
CD3 antibody treatment to mimic T-cell receptor (TCR)
stimulation. In this regard, we found that while the frequency
of IFN-c- or TNF-a-secreting cells in the CD81CD571 T-cell
population was significantly greater than that in the
CD81CD572 T-cell population, there was no difference in
the frequency of IL-17A-secreting cells between the two popu-
lations (Figure 3a). In addition, we examined IFN-c secretion
by CD81CD571 T cells in response to IL-12/IL-18 stimulation
without TCR stimulation and found that CD81CD571 T cells
did not show greater IFN-c secretion than CD81CD572 T cells
a
b
f g
c d e
Singlet gate
FS
C
-H
ei
gh
t
S
S
C
-A
re
a
FSC-Area CD3 [AmCyan]
C
D
8 
[A
P
C
-C
y7
]
CD4 [PE-Cy7]
C
D
57
 [P
ac
ifi
c 
B
lu
e]
CD28 [APC-A]
37.6
57.3
34.6
9.9
11.0
50.5
5.0
4.2
2.3 82.5
FSC-Area
60 **
40
20
%
 C
D
57
+  
ce
lls
in
 C
D
8+
 T
 s
ub
se
t
%
 C
D
28
nu
ll  c
el
ls
in
 C
D
8+
 T
 s
ub
se
t
0
80 * * NS
40
60
20
0
%
 C
D
28
nu
ll  c
el
ls
in
 C
D
4+
 T
 s
ub
se
t
60
40
20
0
%
 C
D
57
+  
ce
lls
in
 C
D
4+
 T
 s
ub
se
t
20
10
15
5
0
Su
rvi
va
l
Survival
C
D
57
CD28
18.3 4.23 34.6 4.95 90
80
P
er
ce
nt
 s
ur
vi
va
l
100
70
150100
Days
log-rank test p=0.004
Low CD8+CD57+
High CD8+CD57+
500 200
50.59.9465.911.6
Ca
rdi
ov
as
cu
lar
mo
rta
lity
Cardiovascular
mortality
Su
rvi
va
l
Ca
rdi
ov
as
cu
lar
mo
rta
lity
Su
rvi
va
l
Ca
rdi
ov
as
cu
lar
mo
rta
lity
Su
rvi
va
l
Ca
rdi
ov
as
cu
lar
mo
rta
lity
S
S
C
-A
re
a
Lymphocyte gate CD3+ gate CD4+ vs CD8+ gate
Figure 1 The frequency of CD81CD571 T cells and short-term cardiovascularmortality in acuteMI patients. The study population was divided into
48 cases of survival and seven cases of cardiovascular mortality, and the frequency of a specific T-cell population was compared between two
patient groups. (a) Gating strategy. (b, c) The frequency of CD571 cells (b) or CD28null cells (c) among CD81 T cells was compared between the two
groups. (d, e) The frequency of CD571 cells (d) or CD28null cells (e) among CD41 T cells was compared between the two groups. Data are
expressed as themeans6s.d. (f) Representative flow cytometry plots are presented for CD57 and CD28 expression in CD81 T cells in patients who
survived (left) and patients who suffered from cardiovascular mortality (right). (g) The patients (48 cases of survival and seven cases of cardio-
vascular mortality) were divided into two groups by median level (25%) of CD571 T cell fraction in the CD81 T-cell population. Kaplan-Meier plot
shows that the 6-month survival rate was significantly lower in patients with CD81CD571 T cells o25% (dotted line) than in patients with
CD81CD571 T cells ,25% (solid line). *P,0.05. MI, myocardial infarction.
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(Figure 3b). These data suggest that the functional activation of
CD81CD571 T cells depends on TCR stimulation rather than
IL-12/IL-18 stimulation. We also evaluated the cytotoxic capa-
city of CD81CD571 T cells vs. CD81CD572 T cells by intra-
cellular staining of cytotoxic granule proteins such as granzyme
A, granzyme B and perforin, and we found that these cytotoxic
granule proteins were highly expressed by the CD81CD571 T-
cell population compared with the CD81CD572 T cell popu-
lation (Figure 3c). Taken together, these data suggest that
CD81CD571 T cells might secrete IFN-c and TNF-a and exert
higher cytotoxic function upon TCR engagement in vivo, and
thus, they might participate in the pathophysiology of an acute
coronary event.
DISCUSSION
In this study, we demonstrated that the frequency of CD571
cells in the CD81 T-cell population is associated with short-
term cardiovascular mortality in patients with acute MI. This
is, to our knowledge, the first demonstration of a relationship
between CD81CD571 T cells and the clinical outcome of acute
coronary syndrome. Immunophenotyping analysis revealed
that CD81CD571 T cells are activated, senescent T cells that
have pro-inflammatory and high cytotoxic capacities and tis-
sue-homing properties.
A role for senescent T cells in atherosclerotic diseases has
been reported in several studies.8,9 Previous studies examining
CD41CD28null T cells as a senescent T-cell population suggested
a role in promoting vascular inflammation in atherosclerotic
diseases, potentially contributing to plaque instability.8 In fact,
CD41CD28null T cells were demonstrated to accumulate in
unstable plaques.9 In this regard, CD41CD28null T cells secrete
high amounts of IFN-c to activate macrophages, which pro-
duce metalloproteinases that degrade the extracellular
matrix.23,24 Furthermore, CD41CD28null T cells release per-
forin and granzymes that lyse endothelial cells and vascular smooth
muscle cells.25 In our study, we focused on CD81CD571 T
cells because cardiovascular mortality was independently asso-
ciated only with the frequency of CD81CD571 T cells and
found that CD81CD571 T cells also demonstrated senescent,
pro-inflammatory and highly cytotoxic properties. Thus, secre-
tion of pro-inflammatory cytokines and the cytotoxic function
of CD81CD571 T cells may affect atherosclerotic plaque
instability, as previously reported for CD41CD28null T cells.
Of note, CD81CD571 T cells hardly produced IL-17A upon
anti-CD3 stimulation (Figure 3a). Considering a recent report
showing that IL-17 stabilizes atherosclerotic plaques through
collagen production,26 the inability of CD81CD571 T cells to
produce IL-17A might also associate with plaque instability in
acute coronary syndrome.
Loss of CD28 expression is a well-known, senescent event of
T cells, and CD28null T cells accumulate with age.27,28 In addi-
tion, loss of CD28 expression is known to be associated with the
expression of CD57, a terminally sulfated glycoprotein.29,30
Therefore, both the CD28null and CD571 phenotypes of T cells
have been consideredmarkers of immunosenescence.15 In fact,
CD81CD28null T cells overlapped significantly with the
CD81CD571 T-cell population in our study (Figure 1f); how-
ever, the short-term cardiovascular mortality of acute MI
patients was independently associated with only the frequency
of CD81CD571 cells (Table 2). Current data suggests that the
CD81CD571T-cell population is distinct fromCD81CD28null
T cells. Brenchley et al.17 found that CD571CD281 and
CD572CD28null T cells both exist in the peripheral blood of
HIV-seropositive patients. Moreover, it was shown that
CD571CD281 and CD571CD28null T cells undergo the same
number of cell divisions and have shorter telomeres than
CD572 T cells, which undergo fewer cell divisions than
CD571 T cells, regardless of the CD28 expression. Together,
these data indicate that CD57 expression better represents T-
cell senescence than the loss of CD28 expression. In addition,
the association between the frequency of CD81CD571 T cells
and cardiovascularmortality suggests that CD81CD571T cells
might be functionally more relevant to the pathogenesis of
acute coronary syndrome thanCD81CD28null T cells. For these
reasons, we focused on elucidating the functional capacity and
antigen reactivity of CD81CD571 T cells in acute MI patients.
We also attempted to identify the stimuli that activate these
senescent T cells and cause them to exert effector functions.
Several studies have reported the relationship between the IL-
12- and IL-18-mediated inflammatory responses and the patho-
physiology and prognosis of atherosclerotic diseases.31–33
Table 2 Multivariate logistic regression analysis for cardio-
vascular mortality controlled for age, gender and left ventricu-
lar ejection fraction
Odds ratio
95% CI
P value
Lower Upper
CD81CD571
Age 1.050 0.936 1.178 0.406
Male sex 0.848 0.055 12.985 0.906
LVEF 0.927 0.844 1.018 0.114
CD81CD571 T cells 1.100 1.013 1.194 0.024*
CD81CD28null
Age 1.061 0.950 1.184 0.295
Male sex 0.530 0.045 6.252 0.614
LVEF 0.915 0.837 1.000 0.051
CD81CD28null T cells 1.069 1.000 1.144 0.052
CD41CD571
Age 1.064 0.957 1.182 0.251
Male sex 0.437 0.039 4.938 0.503
LVEF 0.910 0.829 1.000 0.049*
CD41CD571 T cells 1.204 0.946 1.533 0.131
CD41CD28null
Age 1.087 0.984 1.202 0.102
Male sex 0.313 0.025 3.940 0.369
LVEF 0.925 0.850 1.006 0.069
CD41CD28null T cells 0.994 0.905 1.091 0.892
Abbreviations: CI, Confidence interval; LVEF, left ventricular ejection
fraction.
*P,0.05 is considered significant.
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However, in the current study, the IL-12- and/or IL-18-induced
IFN-c secretion by CD81CD571 T cells was not greater than
that by CD81CD572 T cells (Figure 3b), while anti-CD3 anti-
body-induced IFN-c secretion was significantly higher from the
CD81CD571 T cell population (Figure 3a).
Recently, Hoffmann et al.22 reported the immunophenoty-
pic profiles of T-cell subsets in patients with acuteMI following
primary percutaneous coronary intervention. In that study,
multiparameter flow cytometric analysis revealed that the fre-
quency of CD41CD571 T cells lacking KLRG1 expression were
increased in patients with acute MI. Because CD81CD571 and
CD41CD571 T cells are heterogeneous populations, we must
further investigate which subpopulations within CD81CD571
or CD41CD571 T cells are associated with the development of
acute MI and its outcome.
Although we demonstrated a relationship between the fre-
quency of CD571 cells and acute MI patients, the current data
must be cautiously interpreted. First, we could not examine the
frequency of CD81CD571 T cells prior to acute MI events.
Considering that CD57 is amarker of the replicative senescence
of T cells,15 the frequency of CD81CD571 T cells is not
expected to increase abruptly after acute MI events. However,
the frequencies of CD81CD571 T cells before and after acute
MI events must be analyzed in relation to cardiovascular mor-
tality in the future. Second, the study population did not
include healthy control subjects and thus, immunological char-
acterization of T cells was conducted only in acute MI patients.
A direct comparison of T-cell phenotype and function with
age- and sex-matched healthy subjects would provide a more
valuable immunological perspective for cardiovascular dis-
eases. Third, the small size of the study population and the
limited number of primary endpoints restricted a close analysis
of the frequency of CD81CD571 T cells as a prognostic factor
in acute MI in the current study. In particular, we could not
determine whether these CD81CD571 T cells had an inde-
pendent incremental value over other traditional factors of
cardiovascular mortality in acute MI patients.
In summary, we identified a link between the frequency of
CD81CD571 T cells and short-term cardiovascular mortality
in patients following acute MI. CD81CD571 T cells have sen-
escent, pro-inflammatory and high cytotoxic properties. This
specific subset of T cells might contribute to plaque instability
via high cytotoxic functions and pro-inflammatory cytokines,
including IFN-c and TNF-a. Identification of a pathogenic
CD81 T-cell subset expressing CD57may offer new opportun-
ities for the prevention and treatment of acute MI.
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the recent activation of T cells, such as HLA-DR, PD-1 and FasL (a), markers for the senescence and memory status of T cells, such as CD28, IL-
7Ra and CD45RO (b), natural killer cell-related proteins such as CD56, CD94 and NKG2D (c), tissue-homingmarkers such as CX3CR1 and CCR5
(d) and central-homing markers such as CCR7 and CD62L (e). The P value for each surface marker was calculated using the paired t-test.
**P,0.01. MFI, mean fluorescent intensity; MI, myocardial infarction.
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